Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Rowley

Showing results (201-210 of 208) with videos related to

Pageof 21
Sort By:
You have reached the last page of results.This site can display upto 208 results.
Journal of Medicinal Chemistry|June 23, 1999
Fluorination of 3-(3-(piperidin-1-yl)propyl)indoles and 3-(3-(piperazin-1-yl)propyl)indoles gives selective human 5-HT1D receptor ligands with improved pharmacokinetic profilesM B van Niel, I Collins, M S Beer, et al.
Annals of Neurology|April 24, 2012
FXN methylation predicts expression and clinical outcome in Friedreich ataxiaMarguerite V Evans-Galea, Nissa Carrodus, Simone M Rowley, et al.
The Journal of Pathology|February 13, 2019
Molecular comparison of interval and screen-detected breast cancersDane Cheasley, Na Li, Simone M Rowley, et al.
ACS Medicinal Chemistry Letters|September 24, 2016
Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical CandidateCatherine A Evans, Tao Liu, André Lescarbeau, et al.
Journal of Medicinal Chemistry|January 29, 2024
Discovery and SAR Study of Boronic Acid-Based Selective PDE3B Inhibitors from a Novel DNA-Encoded LibraryAnn M Rowley, Gang Yao, Logan Andrews, et al.
Gynecologic Oncology|January 7, 2020
Therapeutic options for mucinous ovarian carcinomaKylie L Gorringe, Dane Cheasley, Matthew J Wakefield, et al.
Nature Communications|September 4, 2019
The molecular origin and taxonomy of mucinous ovarian carcinomaDane Cheasley, Matthew J Wakefield, Georgina L Ryland, et al.
Journal of Medical Genetics|February 28, 2016
No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testingDouglas F Easton, Fabienne Lesueur, Brennan Decker, et al.
Pageof 21

Showing results (201-210 of 208) with videos related to

Sort By:
Pageof 21
You have reached the last page of results.This site can display upto 208 results.
Journal of Medicinal Chemistry|June 23, 1999
Fluorination of 3-(3-(piperidin-1-yl)propyl)indoles and 3-(3-(piperazin-1-yl)propyl)indoles gives selective human 5-HT1D receptor ligands with improved pharmacokinetic profilesM B van Niel, I Collins, M S Beer, et al.
Annals of Neurology|April 24, 2012
FXN methylation predicts expression and clinical outcome in Friedreich ataxiaMarguerite V Evans-Galea, Nissa Carrodus, Simone M Rowley, et al.
The Journal of Pathology|February 13, 2019
Molecular comparison of interval and screen-detected breast cancersDane Cheasley, Na Li, Simone M Rowley, et al.
ACS Medicinal Chemistry Letters|September 24, 2016
Discovery of a Selective Phosphoinositide-3-Kinase (PI3K)-γ Inhibitor (IPI-549) as an Immuno-Oncology Clinical CandidateCatherine A Evans, Tao Liu, André Lescarbeau, et al.
Journal of Medicinal Chemistry|January 29, 2024
Discovery and SAR Study of Boronic Acid-Based Selective PDE3B Inhibitors from a Novel DNA-Encoded LibraryAnn M Rowley, Gang Yao, Logan Andrews, et al.
Gynecologic Oncology|January 7, 2020
Therapeutic options for mucinous ovarian carcinomaKylie L Gorringe, Dane Cheasley, Matthew J Wakefield, et al.
Nature Communications|September 4, 2019
The molecular origin and taxonomy of mucinous ovarian carcinomaDane Cheasley, Matthew J Wakefield, Georgina L Ryland, et al.
Journal of Medical Genetics|February 28, 2016
No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testingDouglas F Easton, Fabienne Lesueur, Brennan Decker, et al.
Pageof 21